Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Does Kaiser Permanente Cover Vyvanse? Formulary, Prior Auth, and Appeal Steps

By
Published Updated Last reviewed
4 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Drug / Vyvanse (lisdexamfetamine dimesylate), capsules and chewable tablets
  • Manufacturer / Takeda; capsules NDA 021977, chewable tablets NDA 208510 [2][3]
  • Approved uses / ADHD in adults and children 6 and older; moderate to severe binge eating disorder in adults [1]
  • Controlled status / Schedule II, prescription only [1]
  • Kaiser tier and prior authorization / Plan-specific; not in the label or FDA approval records
  • Generic lisdexamfetamine / Capsules and chewable tablets first approved 25 August 2023 [2][4]
  • Arynta oral solution / Lisdexamfetamine 10 mg/mL, approved 16 June 2025 [4]
  • Weight loss / Not an approved use; the label says Vyvanse is not indicated for weight loss [1]

Where Kaiser Permanente's answer lives

Kaiser Permanente's formulary, prior authorization and step-therapy rules are set by the plan and published for its members. The Vyvanse label and the FDA approval records describe the drug, not any plan's tier placement.

What the FDA records say about Vyvanse

Vyvanse capsules in 10, 20, 30, 40, 50, 60 and 70 mg are Takeda's NDA 021977, originally approved on 23 February 2007 as a new molecular entity [2]. The chewable tablets, 10 to 60 mg, are NDA 208510, approved on 28 January 2017 [3]. The current label is effective 30 April 2026, and lisdexamfetamine is a Schedule II controlled substance available by prescription only [1].

The label lists two uses: attention deficit hyperactivity disorder in adults and children 6 years and older, and moderate to severe binge eating disorder in adults [1]. It states that Vyvanse is not indicated for weight loss and that its safety and effectiveness for obesity have not been established [1]. It also says the drug is not recommended in children younger than 6, who had higher plasma exposure and more adverse reactions such as weight loss at the same dose [1].

The label carries a boxed warning for abuse, misuse and addiction. It says Vyvanse has a high potential for abuse and misuse, which can lead to a substance use disorder including addiction [1].

Is there a generic Vyvanse?

Yes. Generic lisdexamfetamine capsules and chewable tablets were first approved on August 25, 2023 [2][4]. The FDA records also list brand Vyvanse capsules and chewable tablets [2][3], and Arynta, a lisdexamfetamine oral solution at 10 mg/mL, approved on June 16, 2025 [4]. Whether a Kaiser plan places a generic on a different tier from brand Vyvanse is not stated in these records.

Frequently asked questions

Does Kaiser Permanente cover Vyvanse?
It depends on the member's plan. The FDA approval record and the Vyvanse label do not state whether a Kaiser plan covers Vyvanse, which tier applies, or whether prior authorization or step therapy is required.
Is Vyvanse approved for weight loss?
No. The label states that Vyvanse is not indicated for weight loss and that its safety and effectiveness for obesity have not been established. Its approved uses are ADHD in adults and children 6 and older, and moderate to severe binge eating disorder in adults [1].
Is there a generic version of Vyvanse?
Yes. Generic lisdexamfetamine capsules and chewable tablets were first approved on August 25, 2023. Arynta is a lisdexamfetamine oral solution at 10 mg/mL that was approved on June 16, 2025 [2][4].
Where do tier, prior authorization and appeal rules come from?
They come from the health plan's own formulary and coverage documents. The FDA records and the Vyvanse label do not describe Kaiser formulary tiers, prior authorization, step therapy or appeal steps.

References

  1. U.S. National Library of Medicine, DailyMed. Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets, Takeda prescribing information. Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets, Takeda label
  2. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
  3. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
  4. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
Evidence overview for Does Kaiser Permanente Cover Vyvanse? Formulary, Prior Auth, and Appeal Steps